Homology Medicines: reverse stock split effective March 26; Nasdaq listing approved for combined company

Q32 Bio Inc.

Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.
Stockholders to receive cash for fractional shares based on March 25 closing price.
Nasdaq Staff approved initial listing application for continued listing of Homology common stock post-merger with Q32.
Reverse split is part of the merger with Q32 Bio Inc.; Q32 will survive as a wholly owned subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.